300,000 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Bought by Bridgeway Capital Management LLC

Bridgeway Capital Management LLC purchased a new position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 300,000 shares of the biotechnology company's stock, valued at approximately $459,000. Bridgeway Capital Management LLC owned approximately 0.20% of Heron Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in HRTX. Nicolet Advisory Services LLC bought a new stake in shares of Heron Therapeutics in the 4th quarter valued at about $25,000. Argent Advisors Inc. acquired a new position in Heron Therapeutics during the fourth quarter worth approximately $31,000. Cutter & CO Brokerage Inc. increased its position in Heron Therapeutics by 69.6% during the fourth quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company's stock worth $51,000 after buying an additional 13,600 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Heron Therapeutics by 23.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,179 shares of the biotechnology company's stock valued at $71,000 after buying an additional 8,684 shares during the last quarter. Finally, Arkadios Wealth Advisors bought a new position in shares of Heron Therapeutics during the 4th quarter worth approximately $76,000. Institutional investors and hedge funds own 80.01% of the company's stock.

Heron Therapeutics Stock Down 2.8%

Shares of HRTX stock opened at $2.11 on Monday. The firm has a 50 day moving average price of $2.19 and a two-hundred day moving average price of $1.82. The company has a market capitalization of $321.91 million, a PE ratio of -11.72 and a beta of 1.33. Heron Therapeutics, Inc. has a 12-month low of $1.04 and a 12-month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The firm had revenue of $38.90 million for the quarter, compared to the consensus estimate of $37.08 million. As a group, research analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on HRTX shares. StockNews.com cut Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. Needham & Company LLC reiterated a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a report on Friday, April 11th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.